Quantcast

Latest Treatments of Parkinson's Disease Stories

2008-09-01 06:00:07

Research and Markets (http://www.researchandmarkets.com/research/9a0ef4/cns_drug_discoveri) has announced the addition of the "CNS Drug Discoveries: Parkinson's Disease Chapter" report to their offering. This chapter of CNS Drug Discoveries focuses on the Parkinson's disease market. In 2007, approximately US$3.6 billion was spent on the symptomatic treatment of Parkinson's disease (PD). Although this neurodegenerative disease affects approximately 1% of the population its prevalence...

2008-08-19 09:01:12

Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced today that it has received Institutional Review Board approvals to begin recruiting and enrolling participants for its Phase 2 clinical trial of the company's gene transfer approach to the treatment of advanced Parkinson's disease. The study is designed to evaluate the safety and efficacy of a novel non-dopaminergic approach for...

2008-07-23 06:00:20

Depomed, Inc. (NASDAQ:DEPO) announced today that it has been awarded a preclinical grant by The Michael J. Fox Foundation under the foundation's Therapeutics Development Initiative 2008 Program. The modest grant amount supports Depomed in the development of novel gastric retentive controlled-release dosage forms of Levodopa/Carbidopa under the hypothesis that Levodopa/Carbidopa's window of absorption in the upper gastrointestinal tract can be optimized using Depomed's AcuForm(TM) technology....

2008-07-14 06:00:12

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that results from the ADAGIO study will be presented at the 12th Congress of European Federation of Neurological Societies (EFNS) on August 26, 2008 in Madrid, Spain. The ADAGIO delayed-start study was designed to demonstrate that AZILECT(R) can slow down the progression of Parkinson's disease. As previously announced, the 1mg dose met all three primary end points, as well as the secondary end point, all with statistical...

2008-06-16 15:00:07

By PETER GOTT Dear Dr. Gott: I was diagnosed with Parkinson's disease in June 2005. I take Mirapex, which is prescribed, and co-enzyme Q10, which is not. I read somewhere that Q10 is a good over-the-counter for people with Parkinson's disease. Could you please comment on this? Dear Reader: Parkinson's is a neurological disorder that results from the loss of brain cells that produce dopamine, a chemical substance that transmits nerve impulses. Dopamine is essential for normal functioning...

2008-06-16 03:00:07

FDA APPROVES REQUIP(R) XL(TM), THE FIRST AND ONLY ORAL ONCE-DAILY NON-ERGOT DOPAMINE AGONIST FOR PARKINSON'S DISEASE Extended-Release Formulation Improved Symptoms in Patients Not Optimally Controlled with Levodopa and Reduced Patients'"Off" Time by Nearly Two Hours Per Day LONDON, UK, 16 June 2008 -- SkyePharma PLC (LSE: SKP) today announces that the United States Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE: GSK) Requip(R) XL(TM) (ropinirole extended-release...

2007-05-08 06:00:11

CAMBRIDGE, Mass. and WINNERSH, U.K., May 8, 2007 (PRIME NEWSWIRE) -- Biogen Idec (Nasdaq:BIIB) and Vernalis plc (Nasdaq:VNLS) (LSE:VER) today announced the initiation of the Phase II program of BIIB014 (also known as V2006), an oral compound, for the treatment of Parkinson's disease. BIIB014 is an adenosine A2A receptor antagonist that may offer a non-dopaminergic therapy for patients with Parkinson's disease. The initial Phase II study is a double-blind, placebo controlled randomised trial...

2005-12-27 14:16:16

NEW YORK (Reuters Health) - Genetically modified nerve 'progenitor' cells can be used as mini-pumps to deliver nerve growth factor to the brain, a new study in animals shows. The results suggest such an approach could be used to treat Parkinson's disease and other brain diseases in humans, Dr. Clive D. Svendsen of the University of Wisconsin-Madison and colleagues report. A nerve growth factor called "glial cell line-derived neurotrophic factor" (abbreviated to GDNF) has been shown...

2005-08-24 16:44:57

A class of drugs known as MAO-B inhibitors may be effective in improving motor symptoms in people with early Parkinson's disease and may delay the need for treatment with other drugs, according to a new systematic review of current evidence. However, contrary to results from other studies, the researchers found that MAO-B (monoamine oxidase B) inhibitors do not appear to slow the disease's progression. " The benefits of MAO-B inhibitors are small but may be worthwhile in some patients," says...

2005-08-24 14:39:00

NEW YORK (Reuters Health) - Drugs called dopamine agonists, used to treat Parkinson's disease, may trigger sudden uncontrollable somnolence in about one in five patients. The side effect has been reported previously in people with Parkinson's disease being treated with dopamine agonists, including Mirapex and Requip, "but controversy persists concerning their nature, severity, and frequency," according to a report in the Archives of Neurology. Dr. Jerry Avorn and colleagues from...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related